| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Stephan Schilling | |
| Inge Lues | |||
| Cynthia A Lemere | |||
| Jens-Ulrich Rahfeld | |||
| P2860 | cites work | Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. | Q51026520 |
| Amyloid-β and Tau in Alzheimer's Disease: Novel Pathomechanisms and Non-Pharmacological Treatment Strategies. | Q51760909 | ||
| Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis. | Q52674162 | ||
| Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). | Q53201871 | ||
| Presenilin-1 mutations in Alzheimer's disease. | Q53235615 | ||
| Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. | Q53446914 | ||
| Dementia | Q56069695 | ||
| On the seeding and oligomerization of pGlu-amyloid peptides (in vitro) | Q79212522 | ||
| Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease | Q87277342 | ||
| The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide | Q21090025 | ||
| Alzheimer's disease | Q22242083 | ||
| Alzheimer's Disease | Q22248111 | ||
| A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline | Q22251083 | ||
| Extracellular phosphorylation of the amyloid β-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease | Q24300656 | ||
| Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges | Q26745928 | ||
| The amyloid hypothesis of Alzheimer's disease at 25 years | Q26749528 | ||
| Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β | Q27674567 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease | Q28005463 | ||
| Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target | Q28238573 | ||
| Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice | Q28300764 | ||
| Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus | Q28592777 | ||
| Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | Q29614407 | ||
| An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice | Q30316057 | ||
| Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides | Q30319086 | ||
| Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. | Q30423789 | ||
| Safety and Efficacy of Scanning Ultrasound Treatment of Aged APP23 Mice. | Q50535401 | ||
| First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease | Q31050126 | ||
| Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach | Q31144656 | ||
| Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. | Q31840691 | ||
| Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques | Q33221293 | ||
| High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain | Q33258748 | ||
| Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study | Q33746272 | ||
| Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis | Q33777535 | ||
| Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup | Q33969633 | ||
| Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process | Q34110227 | ||
| Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study | Q34332159 | ||
| IgG subclasses and allotypes: from structure to effector functions | Q34368678 | ||
| Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 | Q34408888 | ||
| Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies | Q34472054 | ||
| Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. | Q35105102 | ||
| Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease | Q35604177 | ||
| Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody | Q36769531 | ||
| Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials | Q36899566 | ||
| Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies | Q36930444 | ||
| Amyloid-β peptide: Dr. Jekyll or Mr. Hyde? | Q36966660 | ||
| Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study | Q36984142 | ||
| Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation | Q37000563 | ||
| Alzheimer's Aβ42 and Aβ40 peptides form interlaced amyloid fibrils | Q37028176 | ||
| Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models | Q37062829 | ||
| Recent global trends in the prevalence and incidence of dementia, and survival with dementia | Q37139880 | ||
| Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. | Q37504954 | ||
| Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin | Q37519267 | ||
| The Development of New Therapeutics for Alzheimer's Disease | Q37784685 | ||
| The global prevalence of dementia: a systematic review and metaanalysis | Q38073027 | ||
| Development and mechanism of γ-secretase modulators for Alzheimer's disease | Q38101383 | ||
| Alzheimer disease therapy--moving from amyloid-β to tau. | Q38161786 | ||
| Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review). | Q38195746 | ||
| Advances in the management of macular degeneration | Q38214725 | ||
| Truncated and modified amyloid-beta species | Q38230390 | ||
| Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier | Q38351134 | ||
| AChE Inhibitors and NMDA Receptor Antagonists in Advanced Alzheimer's Disease | Q38601811 | ||
| Phosphorylation of amyloid beta (Aβ) peptides - a trigger for formation of toxic aggregates in Alzheimer's disease. | Q38608487 | ||
| Evidence For and Against a Pathogenic Role of Reduced γ-Secretase Activity in Familial Alzheimer's Disease. | Q38802911 | ||
| Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy | Q38818089 | ||
| Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies | Q38826744 | ||
| A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis | Q38913292 | ||
| Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. | Q38959054 | ||
| The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis | Q39003622 | ||
| Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle | Q39035584 | ||
| The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model | Q39432793 | ||
| Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor. | Q40209469 | ||
| Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients | Q40664845 | ||
| Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory | Q41210086 | ||
| APOE genotype and Alzheimer's immunotherapy. | Q42335749 | ||
| Alzheimer's disease drug development pipeline: 2017. | Q42655757 | ||
| Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease | Q42689720 | ||
| Alzheimer's failure raises questions about disease-modifying strategies | Q42872330 | ||
| The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice | Q44557277 | ||
| Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease | Q44915685 | ||
| Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology | Q46330873 | ||
| An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. | Q47393680 | ||
| Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease | Q47552349 | ||
| Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies | Q47565290 | ||
| A Review of the Current Therapies, Challenges, and Future Directions of Transcranial Focused Ultrasound Technology: Advances in Diagnosis and Treatment | Q47580326 | ||
| Fibril structure of amyloid-β(1-42) by cryo-electron microscopy | Q47838176 | ||
| Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed | Q47982970 | ||
| Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease | Q48202279 | ||
| A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice | Q48264364 | ||
| Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease | Q48331917 | ||
| Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains | Q48344258 | ||
| Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates | Q48462637 | ||
| N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation | Q48636044 | ||
| Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits | Q48638383 | ||
| Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains | Q48682997 | ||
| Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation | Q48910328 | ||
| Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease | Q49581840 | ||
| Modulation of mitochondrial bioenergetics as a therapeutic strategy in Alzheimer's disease | Q49940144 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | peptide | Q172847 |
| membrane protein | Q423042 | ||
| blood proteins | Q425056 | ||
| globulins | Q321710 | ||
| monoclonal antibody | Q422248 | ||
| immunotherapy | Q1427096 | ||
| Alzheimer's disease | Q11081 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1068 | |
| P577 | publication date | 2018-05-03 | |
| P1433 | published in | Molecules | Q151332 |
| P1476 | title | Passive Aβ Immunotherapy: Current Achievements and Future Perspectives | |
| P478 | volume | 23 |
| Q93060776 | Aβ43 in human Alzheimer's disease: effects of active Aβ42 immunization |
| Q89866273 | Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation |
| Q92463724 | Low-frequency HIFU induced cancer immunotherapy: tempting challenges and potential opportunities |
| Q92881845 | Neuroinflammation and Neurogenesis in Alzheimer's Disease and Potential Therapeutic Approaches |
Search more.